Home › Companies › Cytek Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Cytek Biosciences, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 10, 2026: 5 items on Cytek Biosciences, Inc.’s Form 8-K, filed June 16, 2026: 3 elected · 2 approved.
Significant dissent: 1 director (24.2% against).
Notable dissent: 1 director (10.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Cytek Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Cytek Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Vera Imper, Ph.D. | 64,769,976 | -- | -- | 20,723,477 | 25,668,037 | 76% | Elected | — |
| Elect Director: Glenn P. Muir | 79,599,103 | -- | -- | 5,894,350 | 25,668,037 | 93% | Elected | — |
| Elect Director: Ming Yan, Ph.D. | 76,741,063 | -- | -- | 8,752,390 | 25,668,037 | 90% | Elected | — |
| 2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 | 84,794,380 | 677,861 | 21,212 | -- | 25,668,037 | 99.2% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 110,533,253 | 479,883 | 148,354 | -- | -- | 99.6% | Approved | — |
Source: Cytek Biosciences, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
See voting trends for Industrials companies, 2025-2026: shareholder support by sector and by company size.
176 asset managers disclosed a vote on at least one Cytek Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Glenn P. Muir
Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Glenn P. Muir”): 79,599,103 for, 5,894,350 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 32,417,672 for, 801,219 withheld, 2,017,909 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,354,659 | 0 | 0 | 0 | For |
| Vanguard | 7,318,136 | 0 | 62 | 0 | For |
| Fidelity | 2,553,604 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 2,017,847 | 0 | Abstain |
| Royce | 1,628,095 | 0 | 0 | 0 | For |
| State Street | 1,213,762 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 973,707 | 0 | 0 | 0 | For |
| Charles Schwab | 911,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,079 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 801,219 | Withhold |
| Dimensional | 785,150 | 0 | 0 | 0 | For |
| Russell Investments | 597,786 | 0 | 0 | 0 | For |
| Equitable | 283,094 | 0 | 0 | 0 | For |
| American Century | 281,578 | 0 | 0 | 0 | For |
| TIAA | 242,355 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 199,155 | 0 | 0 | 0 | For |
| Jackson National | 194,809 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 167,557 | 0 | 0 | 0 | For |
| Lincoln Financial | 167,107 | 0 | 0 | 0 | For |
| JPMorgan | 157,621 | 0 | 0 | 0 | For |
| Invesco | 151,381 | 0 | 0 | 0 | For |
| Voya | 134,598 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,552 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 98,497 | 0 | 0 | 0 | For |
| BNY Mellon | 93,516 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Ming Yan, Ph.D.
Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Ming Yan, Ph.D.”): 76,741,063 for, 8,752,390 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 31,527,416 for, 1,663,325 withheld, 2,046,059 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,354,659 | 0 | 0 | 0 | For |
| Vanguard | 7,284,748 | 0 | 92 | 33,359 | For |
| Fidelity | 2,553,604 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 2,017,847 | 0 | Abstain |
| Royce | 1,628,095 | 0 | 0 | 0 | For |
| State Street | 1,212,252 | 0 | 0 | 1,510 | For |
| Brown Capital Management Mutual Funds | 973,707 | 0 | 0 | 0 | For |
| Charles Schwab | 911,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,079 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 801,219 | Withhold |
| Dimensional | 0 | 0 | 0 | 785,150 | Withhold |
| Russell Investments | 597,786 | 0 | 0 | 0 | For |
| Equitable | 283,094 | 0 | 0 | 0 | For |
| American Century | 281,578 | 0 | 0 | 0 | For |
| TIAA | 242,355 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 199,155 | 0 | 0 | 0 | For |
| Jackson National | 166,689 | 0 | 28,120 | 0 | Mixed |
| Columbia Threadneedle | 167,557 | 0 | 0 | 0 | For |
| Lincoln Financial | 157,831 | 0 | 0 | 9,276 | Mixed |
| JPMorgan | 157,621 | 0 | 0 | 0 | For |
| Invesco | 151,381 | 0 | 0 | 0 | For |
| Voya | 134,598 | 0 | 0 | 0 | For |
| Prudential/PGIM | 96,257 | 0 | 0 | 13,295 | Mixed |
| AIG/SunAmerica | 98,497 | 0 | 0 | 0 | For |
| BNY Mellon | 93,516 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Vera Imper, Ph.D.
Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Vera Imper, Ph.D.”): 64,769,976 for, 20,723,477 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 28,289,297 for, 4,625,628 withheld, 2,321,875 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,354,659 | 0 | 0 | 0 | For |
| Vanguard | 7,267,002 | 0 | 171 | 51,025 | For |
| Fidelity | 2,553,504 | 0 | 0 | 100 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 2,017,847 | 0 | Abstain |
| Royce | 1,628,095 | 0 | 0 | 0 | For |
| State Street | 1,210,750 | 0 | 0 | 3,012 | For |
| Brown Capital Management Mutual Funds | 0 | 0 | 0 | 973,707 | Withhold |
| Charles Schwab | 911,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,079 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 801,219 | Withhold |
| Dimensional | 0 | 0 | 0 | 785,150 | Withhold |
| Russell Investments | 0 | 0 | 0 | 597,786 | Withhold |
| Equitable | 170,788 | 0 | 0 | 112,306 | Mixed |
| American Century | 0 | 0 | 0 | 281,578 | Withhold |
| TIAA | 242,355 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 199,155 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 194,809 | 0 | Abstain |
| Columbia Threadneedle | 167,557 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,000 | 0 | 0 | 85,107 | Mixed |
| JPMorgan | 157,621 | 0 | 0 | 0 | For |
| Invesco | 151,381 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 134,598 | Withhold |
| Prudential/PGIM | 96,257 | 0 | 0 | 13,295 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 98,497 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 93,516 | Withhold |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Prior year: 93.1% for (June 18, 2025 meeting) ▲ 6.1 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in our proxy statement.
Cytek Biosciences, Inc.’s own tally for this item (“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025”): 84,794,380 for, 677,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 was approved based on the following results of voting:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,354,659 | 0 | 0 | 0 | For |
| Vanguard | 7,318,194 | 4 | 0 | 0 | For |
| Fidelity | 2,553,604 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 2,017,847 | 0 | 0 | 0 | For |
| Royce | 1,628,095 | 0 | 0 | 0 | For |
| State Street | 1,213,762 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 973,707 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 920,036 | 0 | 0 | 0 | For |
| Charles Schwab | 911,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,079 | 0 | 0 | 0 | For |
| Dimensional | 785,150 | 0 | 0 | 0 | For |
| Russell Investments | 597,786 | 0 | 0 | 0 | For |
| Equitable | 283,094 | 0 | 0 | 0 | For |
| American Century | 0 | 281,578 | 0 | 0 | Against |
| TIAA | 242,355 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 199,155 | 0 | 0 | 0 | For |
| Jackson National | 194,809 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 167,557 | 0 | 0 | 0 | For |
| Lincoln Financial | 167,107 | 0 | 0 | 0 | For |
| JPMorgan | 157,621 | 0 | 0 | 0 | For |
| Invesco | 151,381 | 0 | 0 | 0 | For |
| Voya | 134,598 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,552 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 98,497 | 0 | 0 | 0 | For |
| BNY Mellon | 93,516 | 0 | 0 | 0 | For |
Fund voting reports, all 58 managers: 35,082,545 for, 281,582 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Topline Capital Management, LLC | 7,141,184 | 0 | 0 | 0 | For |
| HHLR ADVISORS, LTD. | 6,657,030 | 0 | 0 | 0 | For |
| Boston Partners | 5,665,838 | 0 | 0 | 0 | For |
| BlackRock | 3,850,239 | 0 | 0 | 0 | For |
| State Street | 3,482,830 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,775,436 | 0 | 0 | 0 | For |
| BROWN CAPITAL MANAGEMENT LLC | 1,394,698 | 0 | 0 | 0 | For |
| Charles Schwab | 1,106,353 | 0 | 0 | 0 | For |
| Russell Investments | 1,099,553 | 0 | 0 | 0 | For |
| Vanguard | 772,618 | 0 | 0 | 0 | For |
| Northern Trust | 751,727 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 633,639 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 598,653 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 534,082 | 0 | 0 | 0 | For |
| Goldman Sachs | 343,153 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 315,213 | 0 | 0 | 0 | For |
| American Century | 0 | 281,766 | 0 | 0 | Against |
| Dimensional | 258,425 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 257,292 | 0 | 0 | 0 | For |
| Nuveen | 247,066 | 0 | 0 | 0 | For |
| Invesco | 210,149 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 197,863 | 0 | 0 | 0 | For |
| Fidelity | 191,172 | 0 | 0 | 0 | For |
| Legal & General Investment Management America Inc | 0 | 167,321 | 0 | 0 | Against |
| AQR | 158,543 | 0 | 0 | 0 | For |
Institutional-manager reports, all 138 managers: 41,060,280 for, 494,797 against, 11,449 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.6% Approved · of votes cast
Prior year: 92.6% for (June 18, 2025 meeting) ▲ 7.0 pts
Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Cytek Biosciences, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 110,533,253 for, 479,883 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 35,242,668 for, 2,641 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,354,659 | 0 | 0 | 0 | For |
| Vanguard | 7,318,195 | 2 | 0 | 0 | For |
| Fidelity | 2,553,604 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 2,017,847 | 0 | 0 | 0 | For |
| Royce | 1,628,095 | 0 | 0 | 0 | For |
| State Street | 1,213,114 | 648 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 973,707 | 0 | 0 | 0 | For |
| Charles Schwab | 911,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,079 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 801,219 | 0 | 0 | 0 | For |
| Dimensional | 785,150 | 0 | 0 | 0 | For |
| Russell Investments | 597,786 | 0 | 0 | 0 | For |
| Equitable | 283,094 | 0 | 0 | 0 | For |
| American Century | 281,578 | 0 | 0 | 0 | For |
| TIAA | 242,355 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 199,155 | 0 | 0 | 0 | For |
| Jackson National | 194,809 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 167,557 | 0 | 0 | 0 | For |
| Lincoln Financial | 167,107 | 0 | 0 | 0 | For |
| JPMorgan | 157,621 | 0 | 0 | 0 | For |
| Invesco | 151,381 | 0 | 0 | 0 | For |
| Voya | 134,598 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,552 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 98,497 | 0 | 0 | 0 | For |
| BNY Mellon | 93,516 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 129,142,587 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 9.57% |
| 2 | Vanguard | 5.67% |
| 3 | Fidelity | 1.98% |
| 4 | TRUST FOR PROFESSIONAL MANAGERS | 1.56% |
| 5 | Royce | 1.26% |
| 6 | State Street | 0.94% |
| 7 | Brown Capital Management Mutual Funds | 0.75% |
| 8 | RBB FUND, INC. | 0.71% |
| 9 | Charles Schwab | 0.71% |
| 10 | Goldman Sachs | 0.65% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Topline Capital Management, LLC | 5.53% |
| 2 | HHLR ADVISORS, LTD. | 5.15% |
| 3 | Boston Partners | 4.39% |
| 4 | BlackRock | 2.98% |
| 5 | State Street | 2.70% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.15% |
| 7 | BROWN CAPITAL MANAGEMENT LLC | 1.08% |
| 8 | Charles Schwab | 0.86% |
| 9 | Russell Investments | 0.85% |
| 10 | Vanguard | 0.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 17,007,269 | 13.17% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with BlackRock, Inc. | 16,531,858 | 12.80% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Entities affiliated with The Vanguard Group | 7,765,138 | 6.01% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Boston Partners | 7,635,145 | 5.91% | Schedule 13G, filed August 4, 2026 |
| Vanguard Group | 7,475,477 | 5.79% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with Topline Capital Partners, LP | 6,780,847 | 5.25% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Wenbin Jiang, Ph.D. | 6,767,890 | 5.24% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Entities affiliated with Hillhouse Investment Management, Ltd. | 6,657,030 | 5.15% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Millennium Management | 6,291,798 | 4.87% | Form 13F, quarter ended March 31, 2026 |
| Ming Yan, Ph.D. | 5,389,900 | 4.17% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
Percentages above are of 129,142,587 shares outstanding, as reported by Cytek Biosciences, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Cytek Biosciences, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 176 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,246 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers… — Cytek Biosciences, Inc.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cytek Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytek Biosciences, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Cytek Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Cytek Biosciences (CTKB) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytek-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.